Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > lots of misinformation going on here

<< Previous

Bullboard Posts

Next >>

Comment by LifeGoesOn1973on Jan 03, 2020 10:03am

113 Views

Post# 30514788

RE:RE:lots of misinformation going on here

thx Stormdog for the Vascepa correction , I was not aware of it and it never showed up in Vascepa NDA that they filed. but it goes back to the same, if the 20% required from Cape is the pre-adjustment number , then it should be compared to the pre-adjusted value of Vascepa , which is 33%. agree with you it is a slam dunk especially that we reached double the (pre-adjusted) value of vascepa in the 2 g ( capre 15% vs 7% Vascepa) in the high strata

<< Previous

Bullboard Posts

Next >>

3 Canadian companies getting a boost during Stanley Cup Playoffs